Alliance for Pandemic Preparedness

April 30, 2020

Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection

Category:

Topic:

  • This study explores the pharmacokinetic-pharmacodynamic (PK-PD) relationship of chloroquine (CQ) for COVID-19 by modeling both achievable systemic and pulmonary drug concentrations. 
  • CQ is unlikely to achieve systemic levels that would exert meaningful anti-viral activity given its in-vitro pharmacodynamics profile. However, if lung exposure is the driver for CQ’s activity, the simulations shows that currently suggested dosages can be substantially lowered for therapy or prophylaxis.

Aljayyoussi et al. (Apr 30, 2020). Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection. Pre-print downloaded Apr 30 from https://doi.org/10.1101/2020.04.24.20078741